eValuating iDA Selection Ability. The VISA Study.
- Conditions
- InfertilityIVF
- Interventions
- Device: iDAScore®
- Registration Number
- NCT04969822
- Lead Sponsor
- Vitrolife
- Brief Summary
A non-inferiority, prospective parallel group, multi-center, randomized controlled trial to investigate whether selection of a single blastocyst for transfer using the deep learning tool, iDA, results in non-inferior clinical pregnancy rate compared to trained embryologists using standard morphology criteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1066
- Women undergoing IVF or ICSI with controlled ovarian stimulation with gonadotrophins and the intention to treat by either transfer of a single fresh embryo on day 5 or in case of a freeze all cycle, the first rewarmed embryo.
- Age: Up to and including the 42nd completed birthday on the day of randomization.
- Has at least two early blastocysts on day 5.
- Treatment involving donated eggs
- Intention to perform any form of preimplantation genetic testing
- The use of IMSI or polarized light in the ICSI process
- The use of assisted hatching prior to randomization
- Previous participation in this RCT
- Where the cycle is carried out for fertility preservation
- If a day 2-4 transfer is planned
- Has a reduced likelihood of obtaining two early blastocysts on day 5 as evidenced by either: an AMH level of <3pmol/L or AFC <5 (if available)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Embryo selection by iDA iDAScore® Time-lapse videos will be analyzed by iDA and the embryo for fresh transfer on day 5 will be prioritized on the strict basis of the embryo with the highest iDA score. For a frozen cycle; the first embryo to be warmed will be the one with the highest iDA score.
- Primary Outcome Measures
Name Time Method Clinical Pregnancy Rate After 7-9 weeks of gestation Ultrasound evidence of an intrauterine pregnancy with a fetal heart observed
- Secondary Outcome Measures
Name Time Method Live Birth Rate 9 months Defined as the number of patients with at least one live birth after 22 completed weeks of gestation. If the exact gestational age is not known then a birth weight of ≥500gr can be used as a cut-off
Positive hCG Rate Per Randomized Patient Tested on day 9-13 following embryo transfer Defined as the number of patients with a positive β-hCG, determined by a hCG measurement from a blood sample or using urinary sticks
Rate of Non-viable Pregnancies After 7-9 weeks of gestation Defined as the difference between number of clinical pregnancies (excluding ectopic pregnancies) and number of positive β-hCG pregnancies
Ongoing Pregnancy Rate After 7-9 weeks of gestation Defined as the number of patients with a viable pregnancy at ≥12 weeks of gestation
Trial Locations
- Locations (14)
Livio Gothenburg
🇸🇪Gothenburg, Sweden
IVFAustralia Greenwich
🇦🇺Sydney, Greenwich, Australia
IVFAustralia Alexandria
🇦🇺Alexandria, New South Wales, Australia
IVFAustralia, Westmead
🇦🇺Sydney, New South Wales, Australia
Queensland Fertility Group (QFG)
🇦🇺Benowa, Queensland, Australia
Melbourne IVF
🇦🇺East Melbourne, Victoria, Australia
Universitetshospitalet
🇩🇰Aalborg, Denmark
Aagaard Fertilitetsklinik
🇩🇰Aarhus, Denmark
Regionshospitalet
🇩🇰Horsens, Denmark
Reproductive medicine, Sahlgrenska University Hospital
🇸🇪Gothenburg, Sweden
Thames Valley Fertility (TFP)
🇬🇧Maidenhead, United Kingdom
Nurture Fertility (TFP)
🇬🇧Nottingham, United Kingdom
Oxford Fertility (TFP)
🇬🇧Oxford, United Kingdom
Wessex Fertility (TFP)
🇬🇧Southampton, United Kingdom